CL2022003511A1 - Inhibidores de alk2 para el tratamiento de la anemia. - Google Patents

Inhibidores de alk2 para el tratamiento de la anemia.

Info

Publication number
CL2022003511A1
CL2022003511A1 CL2022003511A CL2022003511A CL2022003511A1 CL 2022003511 A1 CL2022003511 A1 CL 2022003511A1 CL 2022003511 A CL2022003511 A CL 2022003511A CL 2022003511 A CL2022003511 A CL 2022003511A CL 2022003511 A1 CL2022003511 A1 CL 2022003511A1
Authority
CL
Chile
Prior art keywords
anemia
treatment
alk2 inhibitors
alk2
inhibitors
Prior art date
Application number
CL2022003511A
Other languages
English (en)
Spanish (es)
Inventor
Yaoyu Chen
Francis Séguy
Ekaterine Asatiani
Original Assignee
Incyte Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte Corp filed Critical Incyte Corp
Publication of CL2022003511A1 publication Critical patent/CL2022003511A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
CL2022003511A 2020-06-16 2022-12-09 Inhibidores de alk2 para el tratamiento de la anemia. CL2022003511A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063039742P 2020-06-16 2020-06-16
US202063056761P 2020-07-27 2020-07-27
US202163152516P 2021-02-23 2021-02-23

Publications (1)

Publication Number Publication Date
CL2022003511A1 true CL2022003511A1 (es) 2023-06-02

Family

ID=76845323

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2022003511A CL2022003511A1 (es) 2020-06-16 2022-12-09 Inhibidores de alk2 para el tratamiento de la anemia.
CL2023001952A CL2023001952A1 (es) 2020-06-16 2023-06-30 Inhibidores de alk2 para el tratamiento de la anemia (divisional).

Family Applications After (1)

Application Number Title Priority Date Filing Date
CL2023001952A CL2023001952A1 (es) 2020-06-16 2023-06-30 Inhibidores de alk2 para el tratamiento de la anemia (divisional).

Country Status (13)

Country Link
US (2) US11723899B2 (cg-RX-API-DMAC7.html)
EP (1) EP4164641A1 (cg-RX-API-DMAC7.html)
JP (1) JP2023530316A (cg-RX-API-DMAC7.html)
KR (1) KR20230025444A (cg-RX-API-DMAC7.html)
CN (1) CN115968289B (cg-RX-API-DMAC7.html)
AU (1) AU2021292484A1 (cg-RX-API-DMAC7.html)
CA (1) CA3187767A1 (cg-RX-API-DMAC7.html)
CL (2) CL2022003511A1 (cg-RX-API-DMAC7.html)
IL (1) IL298767A (cg-RX-API-DMAC7.html)
MX (1) MX2022015900A (cg-RX-API-DMAC7.html)
PH (1) PH12022553501A1 (cg-RX-API-DMAC7.html)
TW (1) TW202214239A (cg-RX-API-DMAC7.html)
WO (1) WO2021257532A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019364415A1 (en) 2018-10-23 2021-05-20 Keros Therapeutics, Inc. ALK2 antibodies and methods of use thereof
TW202131926A (zh) 2019-11-22 2021-09-01 美商英塞特公司 包含alk2抑制劑及jak2抑制劑的組合療法
US12508262B2 (en) 2020-04-30 2025-12-30 Keros Therapeutics, Inc. Methods of using ALK2 inhibitors
IL298767A (en) * 2020-06-16 2023-02-01 Incyte Corp ALK2 inhibitors for the treatment of anemia
WO2022098812A1 (en) 2020-11-04 2022-05-12 Keros Therapeutics, Inc. Methods of treating iron overload
WO2022240948A1 (en) * 2021-05-11 2022-11-17 Keros Therapeutics, Inc. Methods of using alk2 and alk3 antibodies
WO2023198114A1 (zh) * 2022-04-13 2023-10-19 杭州邦顺制药有限公司 Alk2激酶抑制剂

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5077290A (en) 1990-10-11 1991-12-31 Merck & Co., Inc. Morpholine derivatives compositions and use
TW530054B (en) 1997-09-24 2003-05-01 Duphar Int Res New piperazine and piperidine compounds
SE0102439D0 (sv) 2001-07-05 2001-07-05 Astrazeneca Ab New compounds
AU2003234464B2 (en) 2002-05-03 2009-06-04 Exelixis, Inc. Protein kinase modulators and methods of use
AU2003249369A1 (en) 2002-06-21 2004-01-06 Cellular Genomics, Inc. Certain amino-substituted monocycles as kinase modulators
US20040067985A1 (en) 2002-10-04 2004-04-08 Fortuna Haviv Method of inhibiting angiogenesis
SE0203753D0 (sv) 2002-12-17 2002-12-17 Astrazeneca Ab New compounds
WO2004092727A2 (en) 2003-04-11 2004-10-28 Structural Genomix, Inc. Compound libraries and methods for drug discovery
JP4198183B2 (ja) 2004-05-27 2008-12-17 ファイザー・インク 選択的ドーパミンd3アゴニストとしてのアミノピリジン誘導体
SA05260265A (ar) 2004-08-30 2005-12-03 استرازينيكا ايه بي مركبات جديدة
RU2007141401A (ru) 2005-04-08 2009-05-20 ЭЙСАЙ Ар энд Ди МЕНЕДЖМЕНТ КО., ЛТД. (JP) Терапевтический агент для лечения дискинезии
WO2007011760A2 (en) 2005-07-15 2007-01-25 Kalypsys, Inc. Inhibitors of mitotic kinesin
PE20071241A1 (es) 2006-01-17 2008-01-14 Schering Corp Compuestos derivados de hidantoina para el tratamiento de trastornos inflamatorios
EP2069313A2 (en) 2006-06-29 2009-06-17 Alantos Pharmaceuticals Holdings, Inc. Metalloprotease inhibitors
BRPI0914891A2 (pt) 2008-06-20 2015-11-24 Metabolex Inc agonistas de aril gpr119 e usos dos mesmos
EP2655334B1 (en) 2010-12-22 2018-10-03 Eutropics Pharmaceuticals, Inc. Compositions and methods useful for treating diseases
LT2714677T (lt) 2011-05-23 2018-12-10 Merck Patent Gmbh Piridino ir pirazino dariniai
DK2753605T3 (da) 2011-09-09 2019-06-17 Lantheus Medical Imaging Inc Sammensætninger, fremgangsmåder, og systemer til syntesen og anvendelsen af billeddannelsesmidler
JP6430383B2 (ja) 2012-09-28 2018-11-28 ヴァンダービルト ユニバーシティーVanderbilt University 選択的bmp阻害剤としての縮合複素環化合物
EP2964651A4 (en) 2013-03-04 2016-11-30 Brigham & Womens Hospital BMP HEMMER AND METHOD OF USE THEREOF
PT2970205T (pt) 2013-03-14 2019-08-26 Tolero Pharmaceuticals Inc Inibidores da jak2 e da alk2 e métodos para a sua utilização
US10329270B2 (en) 2013-10-21 2019-06-25 Merck Patent Gmbh Heteroaryl compounds as BTK inhibitors and uses thereof
ES2907461T3 (es) 2015-01-20 2022-04-25 Boehringer Ingelheim Animal Health Usa Inc Compuestos antihelmínticos, composiciones y procedimientos de uso de los mismos
EP3344613B1 (en) 2015-08-31 2020-03-04 Dong-A Socio Holdings Co., Ltd. Heteroaryl compounds and their use as therapeutic drugs
KR102359707B1 (ko) * 2016-07-20 2022-02-09 노파르티스 아게 아미노피리딘 유도체 및 이의 선택적 alk-2 억제제로서의 용도
WO2018106820A1 (en) 2016-12-07 2018-06-14 Kura Oncology, Inc. Methods of promoting beta cell proliferation
CA3156007A1 (en) 2019-09-27 2021-04-01 Disc Medicine, Inc. METHODS OF TREATING MYELOFIBROSE AND ASSOCIATED CONDITIONS
US20220372136A1 (en) 2019-09-27 2022-11-24 Disc Medicine, Inc. Methods for treating anemia of chronic disease
TW202131926A (zh) 2019-11-22 2021-09-01 美商英塞特公司 包含alk2抑制劑及jak2抑制劑的組合療法
IL298767A (en) 2020-06-16 2023-02-01 Incyte Corp ALK2 inhibitors for the treatment of anemia

Also Published As

Publication number Publication date
CN115968289A (zh) 2023-04-14
US12383541B2 (en) 2025-08-12
IL298767A (en) 2023-02-01
EP4164641A1 (en) 2023-04-19
PH12022553501A1 (en) 2024-04-22
AU2021292484A1 (en) 2023-01-19
US20230338352A1 (en) 2023-10-26
TW202214239A (zh) 2022-04-16
WO2021257532A1 (en) 2021-12-23
CL2023001952A1 (es) 2023-12-15
MX2022015900A (es) 2023-01-24
CA3187767A1 (en) 2021-12-23
KR20230025444A (ko) 2023-02-21
CN115968289B (zh) 2025-09-30
US11723899B2 (en) 2023-08-15
JP2023530316A (ja) 2023-07-14
US20210393605A1 (en) 2021-12-23

Similar Documents

Publication Publication Date Title
MX2022015900A (es) Inhibidores de alk2 para el tratamiento de la anemia.
BR112023000687A2 (pt) Métodos e combinações de inibidores de kat6 para o tratamento de câncer
CL2021001292A1 (es) Terapia de combinación que incluye un inhibidor de krasg12c y uno o más agentes farmacéuticamente activos adicionales para el tratamiento de cánceres
CL2021002966A1 (es) Combinación de inhibidores de pd-1 e inhibidores de lag-3 para mejorar la eficacia en el tratamiento del cancer.
MX2017010773A (es) Inhibidores de muerte programada 1 (pd-19)/ligando de muerte progamada 1 (pd-l1) para el tratamiento de cancer.
ECSP20069416A (es) Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de jak
MX2024004216A (es) Terapias combinadas de inhibidores de kras g12d con inhibidores de la familia pan erbb.
CR20190162A (es) Métodos para usar un anticuerpo biespecífico que reconoce el factor de coagulación ix y/o el factor de coagulación ix activado y el factor de coagulación x y/o el factor de coagulación x activado
BR112018073920A2 (pt) inibidores de pd-1/pd-l1 para tratamento de câncer".
MX2021008610A (es) Tratamiento del cancer usando combinaciones de inhibidores de erk y raf.
MX2016015434A (es) Combinaciones farmaceuticas para tratar cancer.
CR11510A (es) Uso de un inhibidor de la gamma-secretasa para tratamiento del cancer
MX348941B (es) Medios y metodos para trata y/o prevenir el cancer dependiente del ligando natural de receptor de aril-hidrocarburo.
CR20160308A (es) Combinaciones de inhibidores de histona deacetilasa y farmacos inmunomoduladores
UY33221A (es) MÉTODOS PARA TRATAR CÁNCER USANDO INHIBIDORES DE PI3K Y mTOR EN COMBINACIÓN CON INHIBIDORES DE AUTOFAGIA
EA202190776A1 (ru) Комбинация маломолекулярных ингибиторов cd-47 с другими противораковыми агентами
MX387658B (es) Métodos para tratar y/o prevenir queratosis actínica.
MX2021015770A (es) Inhibidores macrociclicos de mcl-1.
MX2021007565A (es) Composiciones y metodos para la terapia contra el cancer.
DOP2013000131A (es) Composiciones y métodos para tratar el cáncer usando un inhibidor de pi3k y un inhibidor de mek
AR087902A1 (es) COMPOSICIONES Y METODOS PARA TRATAR EL CANCER USANDO EL INHIBIDOR DE PI3Kb Y EL INHIBIDOR DE LA VIA DE MAPK, INCLUIDOS LOS INHIBIDORES DE MEK Y RAF
MX2024003258A (es) Inhibidores de ribonucleotido reductasa (rnr) de sulfonamida ciclica y usos de los mismos.
CL2025001501A1 (es) Inhibidores de proteasas para tratar o prevenir la infección por coronavirus.
MX2021007330A (es) Composiciones y métodos terapéuticos para tratar cáncer usando ácido 6, 8-bis-benciltio-octanoico y un inhibidor de autofagia.
MX2021006915A (es) Inhibidores de cxcr7 para el tratamiento de cancer.